Clik here to view.
ShouTi Secures $100 Million Series B Financing to Accelerate Development of...
SAN FRANCISCO & SHANGHAI ShouTi Inc., a clinical-stage biopharmaceutical company creating life-changing medicines for patients using advanced computational and structure-based technology, today...
View ArticleClik here to view.
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
Aston Sci. Announces the Study Results of Two Therapeutic Cancer Vaccines at...
SEOUL, South Korea Aston Sci., a portfolio model biopharmaceutical company, announced that the study results of its therapeutic cancer vaccine pipelines, AST-301 and AST-021p, will be presented at...
View ArticleClik here to view.
武田薬品工業: 2021年度上期は力強い業績を達成：グローバルブランド14製品の牽引により2021年度末まで成長の勢いが継続する見込み
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE：4502/NYSE:TAK）は、本日、2021年度上期の業績を公表しましたのでお知らせします。上期の力強い業績に基づき、当社は2021年度通期のマネジメントガイダンスを維持します。 グローバルブランド...
View ArticleClik here to view.
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2021 (period ended September 30, 2021). Based...
View ArticleClik here to view.
Fujirebio Europe Receives Translational Research Funding From Alzheimer’s...
GENT, Belgium & TOKYO H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, today announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer’s Drug...
View ArticleClik here to view.
苏爱康与日本化药宣布签署候选新药DARINAPARSIN (SP-02)的日本市场许可协议
东京 (美国商业资讯)–苏爱康制药有限公司（Solasia Pharma K.K，TOKYO: 4597；总部：日本东京；总裁兼首席执行官：Yoshihiro Arai.，以下简称“苏爱康”）和日本化药株式会社（Nippon Kayaku Co., Ltd；TOKYO: 4272；总部：日本东京；总裁：Atsuhiro...
View ArticleClik here to view.
FINVASIA Acquires Gini Health, Expands Into Healthcare Services
CHANDIGARH, India FINVASIA, today, announced its investment in Gini Health, a Canada based healthcare technology company that pioneered DNA and lifestyle data based personalized health to prevent...
View ArticleClik here to view.
Reata Pharmaceuticals Submits Marketing Authorization Application to the...
PLANO, Texas & ZUG, Switzerland Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its...
View ArticleClik here to view.
武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法
日本大阪和伦敦 (美国商业资讯)–武田药品工业株式会社（Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK，简称“武田”）今天宣布行使其收购GammaDelta Therapeutics Limited (“GammaDelta”)的选择权。GammaDelta...
View ArticleClik here to view.
Vernalis Research – a Fully Owned Subsidiary of HitGen Inc – and Hannibal...
CHENGDU, China Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS...
View ArticleClik here to view.
SanBio Announces Publication Comparing Outcome Measures for Persons With...
TOKYO & MOUNTAIN VIEW, Calif. The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan , SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte. Ltd. of Singapore) (TOKYO:4592), hereby...
View ArticleClik here to view.
Clik here to view.
Asensus Surgical Announces Shinmatsudo Central General Hospital in Japan to...
RESEARCH TRIANGLE PARK, N.C. Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of...
View ArticleClik here to view.
Imugene and Eureka Therapeutics Announce Strategic Collaboration to...
SYDNEY & EMERYVILLE, Calif. Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company, and Eureka Therapeutics, Inc. (“Eureka”), a clinical-stage biotechnology company...
View ArticleClik here to view.
CANbridge Pharmaceuticals Enters into Duchenne Muscular Dystrophy Gene...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
bit.bio扩大董事会，新成员包括企业家和诺奖获得者
英格兰剑桥 (美国商业资讯)–今天，bit.bio董事会迎来了三位新成员，他们在将世界一流科学导入新行业并促进公司发展方面均拥有丰富经验。新董事将在bit.bio扩展其专有的合成生物学细胞编程技术平台过程中提供重要指导，帮助创建基于人体细胞的产品和解决方案，从而将医疗行业从侧重于基础研究和药物发现提升为新一代细胞疗法。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleFabrinet Announces First Quarter Fiscal Year 2022 Financial Results
BANGKOK Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of...
View ArticleClik here to view.
Clik here to view.
武田创造强劲的2021财年上半年业绩；受14个全球品牌的推动，增长态势有望进一步持续到财年年底
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TOKYO:4502/NYSE:TAK)（简称“武田”）今天公布了2021财年上半年（截至2021年9月30日）财务业绩。基于上半年强劲的业绩，公司还确认了其2021财年管理层指引。...
View Article